<DOC>
	<DOCNO>NCT02326285</DOCNO>
	<brief_summary>This study design single arm , un-controlled , open-label , multi-center hypothesis generate two-stage phase II trial . It base assumption propose treatment scheme double rate pathologic complete remission Mutated epidermal growth factor receptor ( EGFRmt ) + NSCLC patient compare historical control data standard treatment . Patients NSCLC activate EGFR mutation stage II , IIIA IIIB eligible induction therapy docetaxel cisplatin gefitinib Patients treat 12 day gefitinib 250 mg/day p.o . ( -12 -1 ) induce chemotherapy docetaxel 75 mg/m2 cisplatin 50 mg/m2 d1+2 intercalate gefitinib 250 mg/day d4-20 ( cycle 1 2 ) d4-17 ( cycle3 ) . Surgery plan 4th week d1 last cycle .</brief_summary>
	<brief_title>Induction Therapy With Intercalated Tyrosine Kinase Inhibitor ( TKI ) Chemotherapy NSCLC With Activating Epidermal Growth Factor Receptor ( EGFR ) Mutation Stages II-IIIB</brief_title>
	<detailed_description>Based notion neoadjuvant combination Chemotherapy ( CTx ) intercalate TKI clinically beneficial , inferred prior study data single case report , study aim generate additional information feasibility , safety efficacy treatment approach large group EGFR mutate NSCLC patient . This study hypothesis generate two-stage trial future phase III study neoadjuvant CTx intercalate TKI . Hence , study design rely entirely single treatment arm . To demonstrate efficacy sufficient compare historical data conventional treatment NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm nonsquamous nonsmallcell lung cancer ( NSCLC ) stage II , IIIA IIIB detect preoperatively adequate method activate EGFR mutation exon 1821 deem able undergo curative surgery induction therapy . Stage confirm PETCT well adequate mediastinal staging . MRI brain exclude CNS metastases mandatory . 2 . At least one unidimensionally measurable lesion meeting RECIST criterion ( version 1.1 ) ; 3 . Performance status 0 1 ECOG scale ; 4 . Estimated life expectancy least 12 week ; 5 . Patients age ≥ 18 year ; 6 . Adequate organ function include follow : 1 . Adequate bone marrow reserve : absolute neutrophil ( segmented band ) count ( ANC ) ≥1.5x109/L ; platelet ≥100x109/L ; haemoglobin ≥9 g/dL . 2 . Hepatic : bilirubin ≤ 1xULN ; alkaline phosphatase ( AP ) ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5xULN . 3 . Renal : serum creatinine ≤ 1.3 mg/dL glomerular filtration rate ( GFR ) ≥ 70 mL/min cisplatinum base CTx ; If contraindication include GFR 70mL/minagainst cisplatin exist , carboplatin may also use ; glomerular filtration rate ≥ 30 mL/min ( calculate ) carboplatin use 7 . Adequate lung function test assess body plethysmography , diffusion test necessary spiroergometry . 8 . Cooperation willingness complete aspect study ; Written inform consent participate study . 1 . EGFR wild type configuration ; 2 . EGFR resistance mutation ( i.e . T790M ) ; 3 . Significant cardiovascular disease , uncontrolled hypertension , myocardial infarction within last 6 month , unstable angina pectoris , CHF ≥ NYHA 2 , serious arrhythmia , significant peripheral vascular disease ; 4 . Preexisting neuropathic ≥ grade 2 ; 5 . Patients confirm HIV infection . HIV test mandatory . 6 . Prior history malignancy except basal cell carcinoma carcinoma situ cervix , exception malignancy curative treatment interval least 3 year . 7 . Lactating pregnant woman , woman childbearing potential agree usage highly effective contraception method ( allow method contraception , mean method rate failure le 1 % per year implant , injectable contraceptive , combine oral contraceptive , intrauterine device ( hormonal device ) , sexual abstinence vasectomy partner ) . Woman childbearing potential must negative pregnancy test ( serum βHCG ) visit 1 . 8 . Any chemotherapy start ; 9 . Treatment experimental drug course study within last 30 day 7 halflifes , whatever long duration , prior study start ; 10 . Any psychiatric illness would affect patient 's ability understand demand clinical trial ; 11 . Parallel participation another clinical trial participation another clinical trial within last 30 day 7 halflifes , whatever long duration , prior study start ; 12 . Patient already include trial ; 13 . Patients understand nature , scope consequence clinical trial ; 14 . Affected person might dependent sponsor investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>induction therapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>curative surgery</keyword>
</DOC>